Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 13/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26106632 | 0.91 | IKZF2 (0.47) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL21340298 | 0.90 | IKZF2 (0.51) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL21340272 | 0.90 | IKZF2 (0.51) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL26111730 | 0.89 | IKZF2 (0.50) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL26111071 | 0.89 | IKZF2 (0.50) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL21340278 | 0.89 | IKZF2 (0.48) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL26109181 | 0.89 | IKZF2 (0.49) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL26109197 | 0.88 | IKZF2 (0.49) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL26106148 | 0.88 | IKZF2 (0.49) | IKZF2IKZF1HTR2AHTR2CHTR2B | |
| SCHEMBL26110011 | 0.88 | IKZF2 (0.49) | IKZF2IKZF1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, H1-0, RXFP1 | IKZF2 4353/4885IKZF1 3202/4885HTR2A 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.